COMPASS Pathways plc earnings
Compass’s shares rose 2.1% after the earnings call, a roughly flat reaction. The update centered on completing the COMP360 NDA submission, FDA engagement, and preparations for a potential 2027 launch; approval timing and commercial uptake remain key uncertainties.
- Compass expects to complete its rolling NDA submission within two weeks, supported by two Phase III studies and a Phase IIb study that together enrolled more than 1,000 patients.
- The National Priority Voucher sets a one-to-two-month FDA review target, but the company described approval as a possibility, not a certainty.
- Compass reported $444 million in cash as of September 30 and said it expects funds to carry it through launch and into 2028.
Next report: March 4, 2027 (estimated) · Earnings calendar
Every CMPS quarter
4 quarters, newest first, with how the stock moved after each report.
| Quarter | Reported | Stock after | What happened |
|---|---|---|---|
| Q3 2026 | Nov 7, 2026 | +2.1% | Compass’s shares rose 2.1% after the earnings call, a roughly flat reaction. The update centered on completing the COMP360 NDA submission, FDA engagement, and preparations for a potential 2027 launch; approval timing and commercial uptake remain key uncertainties. |
| Q2 2026 | Aug 10, 2026 | +14.8% | The stock surged 14.8% following the quarter, reflecting strong investor enthusiasm around COMPASS Pathways' highly statistically significant Phase III trial results for COMP360 and clear progress toward an NDA filing and launch readiness. |
| Q1 2026 | May 14, 2026 | +17.0% | The 17% stock rally signals strong investor approval of COMPASS Pathways’ progress toward NDA submission and potential accelerated launch of COMP360 for treatment-resistant depression (TRD), supported by positive Phase III data and regulatory milestones. |
| Q3 2025 | Nov 5, 2025 | Not available | COMPASS Pathways reported significant progress in its Phase III trials for COMP360, with an accelerated NDA filing timeline now targeted for Q1 2026, positioning the company for potential market entry into treatment-resistant depression (TRD). |
Compass’s shares rose 2.1% after the earnings call, a roughly flat reaction. The update centered on completing the COMP360 NDA submission, FDA engagement, and preparations for a potential 2027 launch; approval timing and commercial uptake remain key uncertainties.
Q2 2026Aug 10, 2026+14.8%The stock surged 14.8% following the quarter, reflecting strong investor enthusiasm around COMPASS Pathways' highly statistically significant Phase III trial results for COMP360 and clear progress toward an NDA filing and launch readiness.
Q1 2026May 14, 2026+17.0%The 17% stock rally signals strong investor approval of COMPASS Pathways’ progress toward NDA submission and potential accelerated launch of COMP360 for treatment-resistant depression (TRD), supported by positive Phase III data and regulatory milestones.
Q3 2025Nov 5, 2025COMPASS Pathways reported significant progress in its Phase III trials for COMP360, with an accelerated NDA filing timeline now targeted for Q1 2026, positioning the company for potential market entry into treatment-resistant depression (TRD).
Track earnings for the stocks you own
Add your portfolio once, by connecting your broker or importing your history. When a company you hold reports, you get a recap like this one by email, with how the stock moved.